Formosa Pharmaceuticals Makes First Shipment of APP13007 (Clobetasol Propionate Ophthalmic Suspension, 0.05%) to the United States for Commercialization [Yahoo! Finance]
Eyenovia, Inc. (EYEN)
Last eyenovia, inc. earnings: 3/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=254685&p=irol-irhome
Company Research
Source: Yahoo! Finance
APP13007, developed through Formosa Pharma's proprietary APNT ® nanotechnology platform, is the first drug approved by the U.S. FDA for ophthalmic use utilizing the super-potent corticosteroid, clobetasol propionate. Almost 7 million ophthalmic surgeries are performed annually in the U.S., and the ophthalmic steroid and steroid-combination drug market is valued at USD $1.3 billion . According to a recent survey conducted by Eyenovia of 100 U.S. ophthalmic surgeons, efficacy and cost were identified as the most important factors when choosing a treatment for postoperative inflammation and pain. APP13007 offers a more convenient dosing regimen with its proven efficacy, requiring only twice-daily administration compared to other treatments that require up to four doses per day. Having recently obtained the Drug Export License from Taiwan's Food and Drug Administration (TFDA) in late August, Formosa Pharma has coordinated its first US shipment, a milestone advancement toward global com
Show less
Read more
Impact Snapshot
Event Time:
EYEN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EYEN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EYEN alerts
High impacting Eyenovia, Inc. news events
Weekly update
A roundup of the hottest topics
EYEN
News
- Eyenovia, Inc. (NASDAQ: EYEN) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $2.00 price target on the stock.MarketBeat
- Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device [Yahoo! Finance]Yahoo! Finance
- Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing DeviceGlobeNewswire
- Eyenovia approves 1-for-80 reverse stock split; shares slip [Seeking Alpha]Seeking Alpha
- Eyenovia Announces 1-for-80 Reverse Stock SplitGlobeNewswire
EYEN
Earnings
- 11/12/24 - Beat
EYEN
Sec Filings
- 1/28/25 - Form 8-K
- 1/24/25 - Form 8-K
- 1/16/25 - Form 8-K
- EYEN's page on the SEC website